Geldsegen für Biotechfirma Regenicin insgesammt 6.5Millionen ++ - 500 Beiträge pro Seite

[signaljumper]

Hallo liebe Leser und Leserinnen,


Ich möchte auch eine interessante Aktie vorstellen.

Regenicin Aktie ISIN: US75887Q1022 | WKN: A1C4ZE | Symbol: RGIN
Branche: Biotech

Share Structure
Market Value1 $1,977,668 a/o Nov 19, 2014
Shares Outstanding 135,456,710 a/o Sep 30, 2014

Was macht die Aktie interessant ??
Warum ist die Aktie schon so gut gelaufen ??
und warum hat sie weiteresPotenzial??

Lesen sie die News dazu:
Empfehlenswert auf englisch lesen sonst in google übersetzten.

Regenicin Enters Into Asset Purchase Agreement with Amarantus Bioscience Holdings, Inc.
Print
Alert
Regenicin, Inc. (PC) (USOTC:RGIN)
Intraday Stock Chart

Today : Thursday 20 November 2014
Click Here for more Regenicin, Inc. (PC) Charts.

LITTLE FALLS, N.J., Nov. 19, 2014 /PRNewswire/ -- Regenicin, Inc. (OTC Bulletin Board: RGIN) a biotechnology company specializing in the development of and commercialization of regenerative cell therapies to restore the health of damaged tissues and organs, announced today that it has entered into an Asset Purchase Agreement with Amarantus Bioscience Holdings, Inc. ("Amarantus"). Under the agreement, Amarantus acquires Regenicin rights and claims in the company's litigation currently pending against Lonza Walkersville and Lonza America, Inc. This included all of Regenicin's Cutanagen intellectual property rights and any Lonza manufacturing know-how technology Regenicin may have. In addition, Regencin will sell to Amarantus its PermaDerm trademark and related intellectual property rights associated with it.

The purchase price to be paid by Amarantus consists of $3.5 million in cash, and $3.0 million in (value of) Amarantus common stock. The cash payments were set to be made as follows: $500,000 at the closing, $250,000 on December 31, 2014 and $2,750,000 on January 31, 2015. The $3.0 million in Amarantus common stock was satisfied by the issuance to Regenicin of 37.5 million shares of Amarantus common stock. These shares will be restricted for six months.

Additionally, as part of the agreement, Amarantus agreed to pay Regenicin attorneys on the Lonza litigation, Gordon & Rees, the sum of $450,000, which will satisfy in full, all obligations of Regenicin related to the Lonza litigation. In addition Regenicin granted to Amarantus an exclusive five year option to license any engineered skin product the company develops for the treatment of patients designated as severely burned by the FDA.

As a result of this agreement, Regenicin has been able to conclude the company's participation in the lawsuit with Lonza and continue the company's primary goal of developing and securing approval of life-saving engineered skin substitute products. The proceeds provided under this agreement will greatly enhance the financial condition of the company, funding ongoing development efforts and operating expenses, without the need to incur additional debt or dilute current shareholders.

"We will be reinitiating our communication efforts with shareholders, who were severely restricted under the previous Lonza Agreement and subsequent lawsuit," said Randall McCoy, Regenicin's CEO. "We hope to keep our shareholders and stakeholders fully informed of our progress as we move toward FDA approval of our new product line.

Finally, we wish to thank all our shareholders and stakeholders for their patience and support during the very difficult period now behind us, and we look forward to a successful and rewarding future together."

About Regenicin
Regenicin, Inc. (OTC Bulletin Board: RGIN), is a biotechnology company specializing in the development of regenerative cell therapies to restore the health of damaged tissues and organs. Regenicin, which was founded in 2010, has assembled a world-class management team with a proven track record for developing and bringing innovative medical devices and biotechnology products to market. The company is publicly traded with headquarters in New Jersey. For more information on Regenicin, Inc., as well as its technologies and products, please visit the company website at www.regenicin.com.

Safe Harbor Statement
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are based on the current plans and expectations of management and are subject to a number of uncertainties and risks that could significantly affect the company's current plans and expectations, as well as future results of operations and financial condition. A more extensive listing of risks and factors that may affect the company's business prospects and cause actual results to differ materially from those described in the forward-looking statements can be found in the reports and other documents filed by the company with the Securities and Exchange Commission. The company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

SOURCE Regenicin, Inc.

Copyright 2014 PR Newswire

source:
http://www.otcmarkets.com/stock/RGIN/news


Daraus ergibts sich:

Eine simple Rechnung:

Sie bekommen Aktien von Amarantus Bioscience Holdings, Inc.
im Wert von 3 Millionen $ nach 5 Tagen haltezeit 6 Monate
bzw. 37.5 Millionen Aktien

und 500 000 Dollar nach Börsenschluss.
zusammen
3.5 Millionen nach 5 Tagen
Bei einer Aktienzahl von 135 000 000 Millionen
ergibt das eine Cashposition von
0,026 cent

Nur den Wert an Cash ohne Unternehmenswert ohne ratio

Des weitern erhalten sie
$250,000 on December 31, 2014 and $2,750,000 on January 31, 2015.

sind zusammen nochmals 3 Millionen Dollar / 135 Millionen shares
0,022 cent

D.h. für uns Ende Januar ist das Unternehmen
0,022 + 0,026 = 0,048 cent Wert alleine druch die Geldposition.

Ohne Unternehmenswert und Ratio gerechnet.

Zu den Aktien welche sie erst nach 6 Monaten verkaufen Können.

Amarantus Bioscience Holdings, Inc. ("Amarantus")

ist ein kleines Biotechunternehmen mit sehr grossem Potential,
Warum??

Hier Ihre Pipline mit einigen Blockbustern



homepage:
http://www.amarantus.com/

Schaut euch einfach die Homepage an. Im Managment fidnet Ihr einige grosse Namen.
Oder Ihr schaut hier bei Wins AMBS Board rein.

Chart AMBS:





Wer des Englisch mächtig ist sollte sich zu AMBS auch diesen Artikel durchlesen sehr informativ.
http://bionapcfa.blogspot.ca/
Hier wrden Zahlen von über 20 cent genannt
Alleiniger Wert Engineered Skin Substitute (“ESS”)
das Sie von Regenicin gekauft haben.

D.h. Sollte der Kurs von AMBS steigen prifitiert auf Regenicin davon!!


Des weitern kann man aus den Fillings zu dem Deal entnehmen:

In addition, we granted to Amarantus an exclusive five (5) year option to license any engineered skin designed for the treatment of patients designated as severely burned by the FDA developed by Regenicin. Amrantus can exercise this option at a cost of $10,000,000 USD plus a royalty of 5% on gross revenues in excess of $150M USD.

Source:
http://ih.advfn.com/p.php?pid=nmona&article=64448131

und jetzt zum Kurs:
der liegt aktuell gerade mal bei 0,029 cent
alleine der Cashwert liegt ende Januar bei 0,048 cent
Ratio von 5 wären wir dann bei 20 cent
und das Ohne Kursbewegungen von AMBS.

Alles im allem halte ich den Wert für sehr Interessant.
achja Schuldenfrei sind sie auch.

nachdem sie das Haupgeschäft verkauft haben sollten auch bald news anstehen
wie es weiter geht was entwickelt wird odr ob was gekauft wird.

jetzt der chart:






Grüsse

[Datteljongleur]